2186 Stock Overview
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2186 from our risk checks.
Luye Pharma Group Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.64 |
52 Week High | HK$4.03 |
52 Week Low | HK$2.34 |
Beta | 0.81 |
1 Month Change | -10.81% |
3 Month Change | -18.27% |
1 Year Change | -32.99% |
3 Year Change | -43.71% |
5 Year Change | -62.82% |
Change since IPO | -72.36% |
Recent News & Updates
Recent updates
Shareholder Returns
2186 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | -5.4% | -4.1% | -2.8% |
1Y | -33.0% | -21.9% | -15.0% |
Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: 2186 underperformed the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
2186 volatility | |
---|---|
2186 Average Weekly Movement | 6.1% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.8% |
10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2186's share price has been volatile over the past 3 months.
Volatility Over Time: 2186's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 5,005 | Dian Bo Liu | www.luye.cn |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.
Luye Pharma Group Ltd. Fundamentals Summary
2186 fundamental statistics | |
---|---|
Market cap | HK$9.93b |
Earnings (TTM) | HK$576.26m |
Revenue (TTM) | HK$6.65b |
17.2x
P/E Ratio1.5x
P/S RatioIs 2186 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2186 income statement (TTM) | |
---|---|
Revenue | CN¥6.14b |
Cost of Revenue | CN¥1.94b |
Gross Profit | CN¥4.20b |
Other Expenses | CN¥3.67b |
Earnings | CN¥532.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.14 |
Gross Margin | 68.44% |
Net Profit Margin | 8.67% |
Debt/Equity Ratio | 61.7% |
How did 2186 perform over the long term?
See historical performance and comparison